KR900700089A - 전신성 피부 투과적 투여를 위한 약학적 조성물 - Google Patents

전신성 피부 투과적 투여를 위한 약학적 조성물

Info

Publication number
KR900700089A
KR900700089A KR1019890702205A KR890702205A KR900700089A KR 900700089 A KR900700089 A KR 900700089A KR 1019890702205 A KR1019890702205 A KR 1019890702205A KR 890702205 A KR890702205 A KR 890702205A KR 900700089 A KR900700089 A KR 900700089A
Authority
KR
South Korea
Prior art keywords
propyl
phenyl
pharmaceutical composition
propynylamine
methyl
Prior art date
Application number
KR1019890702205A
Other languages
English (en)
Other versions
KR0136870B1 (ko
Inventor
카로배스 맨프레드
라인 하르트 예르크
Original Assignee
예안 크라메르, 한스 루돌프 하우스
산도즈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10634325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900700089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 예안 크라메르, 한스 루돌프 하우스, 산도즈 아게 filed Critical 예안 크라메르, 한스 루돌프 하우스
Publication of KR900700089A publication Critical patent/KR900700089A/ko
Application granted granted Critical
Publication of KR0136870B1 publication Critical patent/KR0136870B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

전신성 피부 투과적 투여를 위한 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 활성제로 라세미 또는 광학적 활성 형태인 N-메틸-N-(1-페닐-2-프로필)-2-프로피닐아민 또는 그들의 약학적 허용 산 부가염을 투입한 전신적 피부 투과성 투여를 위한 약학적 조성물.
  2. 제1항에 있어서, 상기 활성제는 (-)-형의 히드로클로라이드인 약학적 조성물.
  3. 실시예에 전술된 전신적 피부 투과성 투여를 위한 약학적 조성물.
  4. 전신적 피부 투과성 투여에 적절한 약학적 조성물의 제조에 활성제로서 라세미 형태 또는 광학적 활성 형태인 N-메틸-N-(1-페닐-2-프로필)-2-프로피닐아민 또는 그들의 약학적 허용 산 부가염을 사용하는 방법.
  5. 제2항에 의한 약학적 조성물의 제조에 활성제로서 (-)-N-메틸-N-(1-페닐-2-프로필)-2-프로피닐아민-히드로클로라이드를 사용하는 방법.
  6. 파킨슨씨 질환의 치료에 적절한 전신적 피부 투과성 투여를 위한 약학적 조성물의 제조에 활성제로서 라세미 또는 광학적 활성 형태의 N-메틸-N-(1-페닐-2-프로필)-2-프로피닐아민 또는 그들의 약학적 허용 산부가염을 사용하는 방법.
  7. 파킨슨씨 질환의 치료를 위해 제2항에 의한 약학적 조성물의 제조에 활성제로서 (-)-N-메탈-N-(1-페닐-2-프로필)-2-프로피닐아민-히드로클로라이드를 사용하는 방법.
  8. 피부에 제1항에 의한 약학적 조성물을 적용하는 것으로 구성된 라세미 또는 광학적 활성 형태인 N-메틸-N-(1-페닐-2-프로필)-2-프로피닐아민 또는 그들의 약학적 허용산부가염을 전신적으로 투여하는 방법.
  9. 피부에 제2항에 의한 약학적 조성물을 적용하는 것으로 구성된 (-)-N-메틸-N-(1-페닐-2-프로필)-2-프로피닐 아민-히드로클로라이드를 전신적으로 투여하는 방법.
  10. 제1항에 의한 약학적 조성물을 피부에 적용하여 파킨슨씨 질환으로 고통받는 환자를 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890702205A 1988-03-29 1989-11-28 전신적 경피 투여용 약학적 조성물 KR0136870B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB8807504 1988-03-29
GB888807504A GB8807504D0 (en) 1988-03-29 1988-03-29 Improvements in/relating to organic compounds
GB880.7504 1988-03-29
PCT/EP1989/000291 WO1989009051A1 (en) 1988-03-29 1989-03-18 Deprenyl for systemic transdermal administration
GBPEP89/00291 1989-03-18

Publications (2)

Publication Number Publication Date
KR900700089A true KR900700089A (ko) 1990-08-11
KR0136870B1 KR0136870B1 (ko) 1998-04-25

Family

ID=10634325

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702205A KR0136870B1 (ko) 1988-03-29 1989-11-28 전신적 경피 투여용 약학적 조성물

Country Status (18)

Country Link
EP (1) EP0404807B1 (ko)
JP (1) JP2533211B2 (ko)
KR (1) KR0136870B1 (ko)
AU (1) AU630088B2 (ko)
CA (1) CA1336071C (ko)
DE (1) DE68907406T2 (ko)
ES (1) ES2013129A6 (ko)
FI (1) FI895681A0 (ko)
GB (1) GB8807504D0 (ko)
GR (1) GR1003711B (ko)
HU (1) HU207441B (ko)
IE (1) IE62955B1 (ko)
IL (1) IL89748A (ko)
MY (1) MY105121A (ko)
NZ (1) NZ228467A (ko)
PT (1) PT90120B (ko)
WO (1) WO1989009051A1 (ko)
ZA (1) ZA892321B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
EP0593807A1 (en) * 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5683711A (en) * 1993-04-20 1997-11-04 Hexal Pharma Gmbh Active ingredient patch
WO1995033455A1 (en) * 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19533089C1 (de) 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
WO2000033812A2 (en) † 1998-12-07 2000-06-15 Elan Corporation, Plc Transdermal patch for delivering volatile liquid drugs
EP1441708B1 (en) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1827385B1 (en) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP5754885B2 (ja) * 2007-06-21 2015-07-29 株式会社フジモト・コーポレーション 経皮または経粘膜投与用組成物
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
PT2440228T (pt) 2009-06-08 2018-12-24 Amunix Operating Inc Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
EP2440241B1 (en) 2009-06-08 2017-08-09 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
WO2018071656A1 (en) 2016-10-14 2018-04-19 Knowles Enterprises Inc. Formulations for treatment of migraines
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139127A1 (en) * 1983-08-22 1985-05-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Transdermal drug delivery device and its preparation
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.

Also Published As

Publication number Publication date
CA1336071C (en) 1995-06-27
MY105121A (en) 1994-08-30
EP0404807A1 (en) 1991-01-02
DE68907406T2 (de) 1993-10-14
HU892559D0 (en) 1990-01-28
FI895681A0 (fi) 1989-11-28
GB8807504D0 (en) 1988-05-05
HUT55220A (en) 1991-05-28
DE68907406D1 (de) 1993-08-05
GR890100190A (el) 1990-01-19
JP2533211B2 (ja) 1996-09-11
PT90120A (pt) 1989-11-10
NZ228467A (en) 1991-12-23
IE890921L (en) 1989-09-29
ES2013129A6 (es) 1990-04-16
AU630088B2 (en) 1992-10-22
IL89748A (en) 1993-07-08
JPH02503677A (ja) 1990-11-01
AU3290089A (en) 1989-10-16
WO1989009051A1 (en) 1989-10-05
KR0136870B1 (ko) 1998-04-25
EP0404807B1 (en) 1993-06-30
IE62955B1 (en) 1995-02-20
GR1003711B (el) 2001-10-25
HU207441B (en) 1993-04-28
ZA892321B (en) 1990-12-28
PT90120B (pt) 1994-06-30

Similar Documents

Publication Publication Date Title
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
ES2089027T3 (es) Forma de dosificacion transmucosica.
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
Fisher et al. Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
DK0754034T3 (da) Brusende farmaceutiske formuleringer indeholdende biologisk nedbrydelige mikrokapsler med kontrolleret afgivelse
KR860000865A (ko) 약제 제형의 제조방법
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR880002527A (ko) 신경변질 치료용 안 조성물
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
KR890012942A (ko) 5-치환된 오르니틴 유도체
US4476115A (en) Analgesic composition and method of treating subdermal pain
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
KR880004810A (ko) 소화성 궤양 치료제
KR960003717A (ko) 항암제에 의해 유발되는 말초신경병의 예방에 유용한 의약의 제조를 위한 엘리프로딜 및 그 거울상이성질체의 이용
KR890007728A (ko) 진통제 제조방법
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
Harris et al. Ocular Anti-inflammatory Effect of Fenoprofen: Dose-Response Study
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090123

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee